Allogene Therapeutics shares rise 2.68% premarket after Tevogen Bio Holdings Inc. published positive clinical trial data for TVGN 489.

Allogene Therapeutics, Inc. rose 2.68% in premarket trading. The company's stock price increase may be attributed to the recent news from Tevogen Bio Holdings Inc. (TVGN), which highlighted the importance of precision treatments for individuals with weakened immune systems. Tevogen's TVGN 489, an investigational allogeneic SARS-CoV-2-specific Cytotoxic CD8+ T lymphocyte (CTL) immunotherapy, has shown positive proof-of-concept/dose-finding clinical trial data. This news may have positively influenced investor sentiment towards Allogene Therapeutics, Inc., given its focus on cell therapies.